Comparative Efficiency of Prostate-Specific Antigen Screening Strategies for Prostate Cancer Detection
Article Abstract:
PSA testing at the age of 40, 45, and then every two years beginning at the age of 50 reduces mortality rates from prostate cancer while saving money from reduced PSA testing and fewer biopsies. PSA testing is used to diagnose prostate cancer in men. Many doctors believe in annual PSA tests beginning at 50.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
Article Abstract:
Increased blood levels of prostate-specific antigen (PSA) as men age may indicate greater risk for developing prostate cancer and other prostate diseases than in men with lower blood levels of PSA. Of 54 men whose blood levels of androgen and PSA were measured over seven to 25 years, 16 did not develop prostate disease, 20 developed benign prostatic hyperplasia (enlargement) (BPH), and 18 developed prostate cancer. Men who developed prostate cancer had a more rapid increase in PSA levels with age than men who developed BPH. Men who developed BPH had a more rapid increase in PSA levels with age than men who did not develop prostate disease. Five years before diagnosis, changes in PSA levels among men who developed BPH were approximately the same as those of men who did not develop prostate disease. The PSA levels of men who developed prostate cancer increased at a much more rapid rate compared to the other two groups, however.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1992
User Contributions:
Comment about this article or add new information about this topic:
Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer
Article Abstract:
Men with prostate-specific antigen (PSA) levels less than 2 nanograms per milliliter (ng/ml) who have no clinical signs of prostate cancer should only be screened with PSA testing every two years. Researchers associated with the Baltimore Longitudinal Study of Aging analyzed PSA levels in 40 men who developed prostate cancer and 272 without the disease. Men with PSA levels below 2 ng/ml were unlikely to experience elevated levels even after four years and 94% of the cancers found in these men were curable. On the other hand, 30% of the cancers found in men with PSA levels greater than 5 ng/ml were incurable. These men may require annual screening.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas
- Abstracts: An appraisal of treatment guidelines for antepartum community-acquired pneumonia. Acute pancreatitis in pregnancy
- Abstracts: Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
- Abstracts: A 69-year-old renal-transplant recipient with low-grade fever and multiple pulmonary nodules. A 19-year-old man with fever, abdominal pain, anemia and a left renal mass. (Case 38-1989)